Neurodegeneration with Brain Iron Accumulation: Clinicoradiological Approach to Diagnosis

Journal of Neuroimaging

Volumn 25, Issue 4, 2015, Pages 539-551

  Amaral, Lázaro L F ^a,b   Gaddikeri, Santhosh ^c   Chapman, Philip R ^d   Roy, Rasmoni ^e   Gaddikeri, Ramya S ^f   Marussi, Victor Hugo ^a   Bag, Asim K ^d  

^a HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^b Santa Casa de Misericordia de Sao Paulo   (Brazil)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

Author keywords

BPAN; Imaging; MPAN; MRI; NBIA; PKAN; PLAN; SENDA

Indexed keywords

ACERULOPLASMINEMIA; ALGORITHM; ARTICLE; BETA PROPELLER PROTEIN ASSOCIATED NEURODEGENERATION; FATTY ACID HYDROXYLASE ASSOCIATED NEURODEGENERATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KUFOR RAKEB DISEASE; MITOCHONDRIAL MEMBRANE PROTEIN ASSOCIATED NEURODEGENERATION; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NEUROIMAGING; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHOLIPASE ASSOCIATED NEURODEGENERATION; WOODHOUSE SAKATI SYNDROME; BRAIN; GENETIC PREDISPOSITION; GENETICS; IMAGE ENHANCEMENT; IRON OVERLOAD; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROCEDURES;

BRAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMAGE ENHANCEMENT; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES;

EID: 84937028955     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/jon.12195     Document Type: Article

References (67)

1. Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Movement Disord 2012;27:42-53.
2. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. New Engl J Med 2003;348:33-40.
3. Kruer MC. Introduction. Semin Pediatr Neurol 2012;19:49-50.
4. Kruer MC, Boddaert N. Neurodegeneration with brain iron accumulation: a diagnostic algorithm. Semin Pediatr Neurol 2012;19:67-74.
5. Kruer MC, Boddaert N, Schneider SA, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol 2012;33:407-414.
6. Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996;14:479-481.
7. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349.
8. Schneider SA, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation. Semin Pediatr Neurol 2012;19:57-66.
9. Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol 2005;43:286-296.
10. Marelli C, Piacentini S, Garavaglia B, et al. Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Movement Disord 2005;20:208-212.
11. Egan RA, Weleber RG, Hogarth P, et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol 2005;140:267-274.
12. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009;46:73-80.
13. Chavhan GB, Shroff MM. Twenty classic signs in neuroradiology: a pictorial essay. Ind J Radiol Imag 2009;19:135-145.
14. Sethi KD, Adams RJ, Loring DW, et al. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988;24:692-694.
15. Sharma MC, Aggarwal N, Bihari M, et al. Hallervorden-Spatz disease: MR and pathological findings of a rare case. Neurol India 2005;53:102-104.
16. Schaffert DA, Johnsen SD, Johnson PC, et al. Magnetic resonance imaging in pathologically proven Hallervorden-Spatz disease. Neurology 1989;39:440-442.
17. Kruer MC, Hiken M, Gregory A, et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011;134:947-958.
18. Guillerman RP. The eye-of-the-tiger sign. Radiology 2000;217:895-896.
19. Schneider SA, Hardy J, Bhatia KP. Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential? J Neurol Neurosurg Psychiatry 2009;80:589-590.
20. Hayflick SJ, Penzien JM, Michl W, et al. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:166-169.
21. Hartig MB, Hortnagel K, Garavaglia B, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006;59:248-256.
22. Zolkipli Z, Dahmoush H, Saunders DE, et al. Pantothenate kinase 2 mutation with classic pantothenate-kinase-associated neurodegeneration without 'eye-of-the-tiger' sign on MRI in a pair of siblings. Pediatr Radiol 2006;36:884-886.
23. Baumeister FA, Auer DP, Hortnagel K, et al. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005;36:221-222.
24. Schipper HM. Neurodegeneration with brain iron accumulation - clinical syndromes and neuroimaging. Biochim Biophys Acta 2012;1822:350-360.
25. Chang CL, Lin CM. Eye-of-the-tiger sign is not pathognomonic of pantothenate kinase-associated neurodegeneration in adult cases. Brain Behav 2011;1:55-56.
26. McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008;70:1614-1619.
27. Molinuevo JL, Munoz E, Valldeoriola F, et al. The eye of the tiger sign in cortical-basal ganglionic degeneration. Movement Disord 1999;14:169-171.
28. Strecker K, Hesse S, Wegner F, et al. Eye of the tiger sign in multiple system atrophy. Eur J Neurol 2007;14:e1-e2.
29. van den Bogaard SJ, Kruit MC, Dumas EM, et al. Eye-of-the-tiger-sign in a 48 year healthy adult. J Neurol Sci 2014;336:254-256.
30. Kumar N, Boes CJ, Babovic-Vuksanovic D, et al. The "eye-of-the-tiger" sign is not pathognomonic of the PANK2 mutation. Arch Neurol 2006;63:292-293.
31. Cossu G, Cella C, Melis M, et al. [123I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in PANK2 gene. Neurology 2005;64:167-168.
32. Liman J, Wellmer A, Rostasy K, et al. Transcranial ultrasound in neurodegeneration with brain iron accumulation (NBIA). Eur J Paediatr Neurol 2012;16:175-178.
33. Kostic VS, Svetel M, Mijajlovic M, et al. Transcranial sonography in pantothenate kinase-associated neurodegeneration. J Neurol 2012;259:959-964.
34. Paisan-Ruiz C, Li A, Schneider SA, et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2012;33:814-823.
35. Gregory A, Hayflick S. Neurodegeneration with brain iron accumulation disorders overview. In: Pagon RA, Adam MP, Bird TD, et al., eds. Gene Reviews. Seattle, WA: University of Washington. 2013:1993-2014.
36. Schneider SA, Dusek P, Hardy J, et al. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol 2013;11:59-79.
37. Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008;71:1402-1409.
38. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006;38:752-754.
39. Kurian MA, Morgan NV, MacPherson L, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008;70:1623-1629.
40. Kruer MC, Paisan-Ruiz C, Boddaert N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010;68:611-618.
41. Saitsu H, Nishimura T, Muramatsu K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 2013;45:445-449, 9e1.
42. Hayflick SJ, Kruer MC, Gregory A, et al. Beta-propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 2013;136:1708-1717.
43. Hartig MB, Iuso A, Haack T, et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 2011;89:543-550.
44. Hogarth P, Gregory A, Kruer MC, et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013;80:268-275.
45. Hartig M, Prokisch H, Meitinger T, et al. Mitochondrial membrane protein-associated neurodegeneration (MPAN). Int Rev Neurobiol 2013;110:73-84.
46. Miyajima H, Nishimura Y, Mizoguchi K, et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987;37:761-767.
47. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003;23:345-350.
48. McNeill A, Pandolfo M, Kuhn J, et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008;60:200-205.
49. Merle U, Tuma S, Herrmann T, et al. Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. J Gastroen Hepatol 2010;25:1144-1150.
50. Yoshida K, Kaneko K, Miyajima H, et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 2000;175:91-95.
51. Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007;130:110-119.
52. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354.
53. Wills AJ, Sawle GV, Guilbert PR, et al. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry 2002;73:91-92.
54. Fatima Z, Ishigame K, Araki T. Case 193: Neuroferritinopathy-a brain iron accumulation and neurodegenerative disorder. Radiology 2013;267:650-655.
55. Najim al-Din AS, Wriekat A, Mubaidin A, et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994;89:347-352.
56. Park JS, Mehta P, Cooper AA, et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat 2011;32:956-964.
57. Matsui H, Sato F, Sato S, et al. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS Lett 2013;587:1316-1325.
58. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Movement Disord 2010;25:979-984.
59. Williams DR, Hadeed A, al-Din AS, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Movement Disord 2005;20:1264-1271.
60. Bruggemann N, Hagenah J, Reetz K, et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010;67:1357-1363.
61. Santoro L, Breedveld GJ, Manganelli F, et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011;12:33-39.
62. Crosiers D, Ceulemans B, Meeus B, et al. Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. Parkinsonism Relat D 2011;17:135-138.
63. Eiberg H, Hansen L, Korbo L, et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clin Genet 2012;82:256-263.
64. Woodhouse NJ, Sakati NA. A syndrome of hypogonadism, alopecia, diabetes mellitus, mental retardation, deafness, and ECG abnormalities. J Med Genet 1983;20:216-219.
65. Ben-Omran T, Ali R, Almureikhi M, et al. Phenotypic heterogeneity in Woodhouse-Sakati syndrome: two new families with a mutation in the C2orf37 gene. Am J Med Genet Part A 2011;155A:2647-2653.
66. Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005;57:738-741.
67. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011;118:473-477.